American Shared Hospital Services — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; compared with FY2019. This is an annual report, not a standalone fourth-quarter filing. The company provides Gamma Knife radiosurgery and proton beam radiation therapy (PBRT) equipment and services in the United States and Latin America.
Financial results
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $17.837 million | $20.605 million |
| Gross margin | $4.466 million; 25.0% of revenue | $6.920 million; 33.6% |
| Operating income (loss) | $(9.463) million | $1.542 million |
| Net income (loss) attributable to ASHS | $(7.058) million; $(1.14) per diluted share | $0.659 million; $0.11 per diluted share |
| Cash provided by operating activities | $9.745 million | $8.047 million |
| Cash, cash equivalents and restricted cash | $4.325 million | $1.779 million |
| Long-term debt and finance leases | $13.516 million | Not stated as a combined figure |
| Working capital | $(1.530) million | $2.528 million |
Revenue declined 13.4%. Gamma Knife generated $11.670 million, down 13.9%, while PBRT generated $6.167 million, down 0.8%. IGRT revenue fell to zero from $0.840 million after the contract ended and equipment was sold. Costs of revenue decreased 2.3%, but rose to 75.0% of revenue from 66.4%; selling and administrative expense increased 13.5% to $4.608 million. Interest expense declined to $1.057 million from $1.318 million.
The company recorded an $8.264 million impairment and associated removal-cost charge, compared with none in 2019. The filing attributes the net loss primarily to this charge. Income tax benefit was $1.737 million, versus $0.128 million tax expense in 2019.
Business changes and material events
- In June 2020, the company acquired Gamma Knife Center Ecuador (GKCE); ownership reached approximately 99.3% by year-end. The transaction’s base price was $2.0 million, funded with $575,000 cash and a $1.425 million DFC loan. Further working-capital and contingent payments were disclosed.
- The company impaired six Gamma Knife units and related removal costs, totaling $4.401 million, citing units already removed or expected to leave service and uncertainty around customer renewals. It also impaired deposits and related costs for two unplaced PBRT systems by $3.863 million.
- One customer represented approximately 35% of 2020 revenue, compared with 30% in 2019; four customers together represented approximately half of 2020 revenue. Several Gamma Knife customers gave notice of nonrenewal or termination.
- Gamma Knife procedures increased to 1,530 from 1,498, partly reflecting the Ecuador acquisition, but average revenue per procedure fell 14.2% to $7,763. PBRT fractions declined 2.5% to 5,868.
Liquidity, commitments and outlook
Operating cash flow was $9.745 million, while investing activities used $2.389 million and financing activities used $4.810 million. Receivables declined to $4.303 million from $6.894 million, and days sales outstanding fell to 88 from 122. Management said cash on hand, operating cash flow and other resources should cover scheduled debt and finance-lease obligations for the next 12 months, while noting future financing availability is not assured.
Current liabilities exceeded current assets by $1.530 million. Debt and finance-lease obligations totaled $13.516 million at year-end; finance leases included $5.945 million current and $2.974 million long-term. The company disclosed total commitments of $72.894 million, including $46.210 million of future equipment purchases and $10.493 million of equipment service contracts. The equipment-purchase schedule places $44.035 million in 2022–2023; management stated there were no significant cash requirements for Gamma Knife and LINAC commitments in the next 12 months, pending financing.
COVID-19 delayed treatments and commercial activity and reduced patient volumes, with effects varying by site. Management provided no quantified earnings or revenue guidance. The Radiation Oncology Alternative Payment Model is scheduled to begin in 2022; four Gamma Knife sites were selected, while the PBRT site was not. The company did not expect a significant Gamma Knife revenue impact from participation, but reimbursement and adoption remain risks.
Investor verification priorities
- Reconcile the impairment disclosures: the income statement reports $8.264 million, while the cash-flow statement lists an $8.184 million impairment add-back.
- Assess the outlook for customer renewals, the impact of terminated contracts, and dependence on major customers—especially the customer contributing 35% of revenue.
- Review the timing, financing, and potential cancellation or deposit-loss exposure for the $46.210 million equipment-purchase commitments, including the two unplaced PBRT systems.
- Evaluate whether operating cash flow can sustain debt and lease payments given the working-capital deficit and substantial near-term finance-lease maturities.
- Track post-acquisition GKCE purchase-price adjustments and the remaining minority interest, as well as recovery in treatment volumes and reimbursement rates.